(NASDAQ: FTH) Faeth Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.35%.
Faeth Therapeutics's earnings in 2026 is -$195,529,000.On average, 12 Wall Street analysts forecast FTH's earnings for 2026 to be -$675,561,735, with the lowest FTH earnings forecast at -$3,437,934,176, and the highest FTH earnings forecast at -$81,126,014. On average, 12 Wall Street analysts forecast FTH's earnings for 2027 to be -$88,679,171, with the lowest FTH earnings forecast at -$136,241,057, and the highest FTH earnings forecast at -$70,001,711.
In 2028, FTH is forecast to generate -$95,147,029 in earnings, with the lowest earnings forecast at -$159,032,312 and the highest earnings forecast at -$64,303,898.